Journal Mobile Options
Table of Contents
Vol. 94, No. 2, 2003
Issue release date: June 2003
Nephron Clin Pract 2003;94:c33–c39
(DOI:10.1159/000071279)

Hemoperfusion with Polymyxin B-Immobilized Fiber in Septic Patients with Methicillin-Resistant Staphylococcus aureus-Associated Glomerulonephritis

Nakamura T. · Ushiyama C. · Suzuki Y. · Osada S. · Inoue T. · Shoji H. · Hara M. · Shimada N. · Koide H.
Departments of aMedicine and bSurgery, Misato Junshin Hospital, cDepartment of Medicine, National Rehabilitation Center, and dDepartment of Cardiology, Koshigaya Hospital, Dokkyo University School of Medicine, Saitama; eArtificial Organ Department, Toray Medical Co., Ltd., Tokyo; fDepartment of Pediatrics, Yoshida Hospital, Niigata; gDepartment of Medicine, Koto Hospital, Tokyo, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: We investigated whether urinary podocytes are present in septic patients with methicillin-resistant Staphylococcus aureus (MRSA)-associated glomerulonephritis and whether polymyxin B-immobilized fiber (PMX-F) treatment affects proteinuria and urinary podocyte excretion in these patients. Methods: Twenty septic patients with MRSA-associated glomerulonephritis (mean age: 63.7 years) and 80 septic patients whose MRSA infection was not followed by glomerulonephritis (mean age: 60.5 years) were included in this study. All septic patients were treated with fosfomycin sodium, β-lactams, arbekacin sulfate, and teicoplanin, or a combination of these. Twenty septic patients with MRSA-associated glomerulonephritis were randomly assigned to one of two treatments: PMX-F treatment (group A, n = 10) and conventional treatment (group B, n = 10). PMX-F treatment was repeated twice. Results: Urinary podocytes and urinary protein excretion were not detected in MRSA septic patients without glomerulonephritis. However, urinary podocytes (1.7 ± 0.6 cells/ml) and proteinuria (2.6 ± 0.6 g/d) were detected in the 20 septic patients with MRSA-associated glomerulonephritis. Plasma endotoxin levels were decreased from 13.6 ± 4.6 pg/ml to 6.6 ± 2.2 pg/ml (p < 0.05) in group A. Levels in group B, however, showed little difference after treatment. Urinary podocytes were reduced in group A (from 1.8 ± 0.6 cells/ml to 0.4 ± 0.2 cells/ml, p < 0.01) as was urinary protein excretion (from 3.0 ± 0.5 g/d to 0.8 ± 0.4 g/d, p < 0.01) but urinary podocytes and protein excretion levels showed little difference after treatment in group B. Conclusion: PMX-F treatment may be effective in reducing urinary protein and urinary podocyte excretion in septic patients with MRSA-associated glomerulonephritis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Koyama A, Kobayashi M, Yamaguchi N, Yamagata K, Takano K, Nakajima M, Irie F, Goto M, Igarashi M, Iitsuka T, Aoki Y, Sakurai H, Sakurayama N, Fukao K: Glomerulonephritis associated with MRSA infection: A possible role of bacterial superantigen. Kidney Int 1995;47:207–216.
  2. Yoh K, Kobayashi M, Yamaguchi N, Hirayama K, Ishizu T, Kikuchi S, Iwabuchi S, Muro K, Nagase S, Aoyagi K, Kondoh M, Takemura K, Yamagata K, Koyama A: Cytokines and T-cell responses in superantigen-related glomerulonephritis following methicillin-resistant Staphylococcus aureus infection. Nephrol Dial Transplant 2000;15:1170–1174.

    External Resources

  3. Yoh K, Kobayashi M, Hirayama A, Hirayama K, Yamaguchi N, Nagase S, Koyama A: A case of superantigen-related glomerulonephritis after methicillin-resistant Staphylococcus aureus (MRSA) infection. Clin Nephrol 1997;48:311–316.
  4. Yamashita Y, Tanase T, Terada Y, Tamura H, Akiba T, Inoue H, Ida T, Sasaki S, Marumo F, Nakamoto Y: Glomerulonephritis after methicillin-resistant Staphylococcus aureus infection resulting in end-stage renal failure. Intern Med 2001;40:424–427.
  5. Bantar C, Durlach R, Nicola F, Freuler C, Bonvehi P, Vazquez R, Smayevsky J: Efficacy and pharmadynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infection. J Antimicrob Chemother 1999;43:737–740.

    External Resources

  6. De Lalla F, Viola R, Pellizzer G, Lazzarini L, Tramarin A, Fabris P: Regional prophylaxis with teicoplanin in monolateral or bilateral total knee replacement: An open study. Antimicrob Agents Chemother 2000;44:316–319.
  7. Bellomo R, Baldwin I, Ronco C: Extracorporeal blood purification therapy for sepsis and systemic inflammation: Its biological rationale. Contrib Nephrol. Basel, Karger, 2001, vol 132, pp 367–374.
  8. Kodama M, Tani T, Hanasawa K, Hirata K, Hirasawa H, Osa S, Otsuka T, Tamamoto Y, Kanesaka S, Takahashi Y, Maekawa K, Wakabayashi Y, Tamakuma S, Sugimoto T, The PMX Clinical Study Group: Treatment of sepsis by plasma endotoxin removal. Hemoperfusion using a polymyxin-B immobilized column. J Endotoxin Res 1997;4:293–300.
  9. Shoji H, Tani T, Hanasawa K, Kodama M: Extracorporeal endotoxin removal by polymyxin B-immobilized fiber cartridge: Designing and antiendotoxin efficacy in the clinical application. Ther Apher 1998;2:3–12.
  10. Nakamura T, Ebihara I, Shimada N, Koide H: Changes in plasma erythropoietin and interleukin-6 concentrations in patients with septic shock after hemoperfusion with polymyxin B-immobilized fiber. Int Care Med 1998;24:1272–1276.
  11. Nakamura T, Ebihara I, Shoji H, Ushiyama C, Suzuki S, Koide H: Treatment with polymyxin B-immobilized fiber reduced platelet activation in septic shock patients: Decrease in plasma levels of soluble P-selectin, platelet factor-4 and β-thromboglobulin. Inflam Res 1999;48:171–175.
  12. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H: Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci 2000;320:112–116.
  13. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H: The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal change nephrotic syndrome. Am J Nephrol 2000;20:175–179.
  14. Churg J, Bernstein J, Glassock RJ (eds). Renal Disease. Classification and Atlas of Glomerular Diseases, ed 2. New York, Igakushoin, 1995.
  15. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medline. Chest 1992;101:1644–1655.
  16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: A severity of disease classification system. Crit Care Med 1985;13;818–829.
  17. Hara M, Yamamoto T, Yanagihara T, Takada T, Itoh M, Adachi Y, Yoshizumi A, Kawasaki K, Kihara I: Urinary excretion of podocalyxin indicates glomerular epithelial cell injuries in glomerulonephritis. Nephron 1995;69:397–403.
  18. Hara M, Yanagihara T, Takada T, Itoh M, Matsuno M, Yamamoto T, Kihara I: Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 1998;18:35–41.
  19. Brun-Buisson C, Doyan F, Carlet J: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. JAMA 1995;274:968–974.
  20. Friedman G, Silva E, Vincent J: Has the mortality of septic shock changed with time? Crit Care Med 1998;26:2078–2086.
  21. Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL, Tellado JM, Salgado-Remigio A, Zimlichman R, Withington S, Tschaikowsky K, Brase R, Damas P, Kupper H, Kempeni J, Eiselstein J, Kaul M: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001;29:765–769.
  22. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lein D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der Auwera P: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter-phase III trial with 1,342 patients. Crit Care Med 2001;29:503–510.
  23. Opal SM, Cohen J: Clinical gram-positive sepsis: Does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 1999;27:1608–1616.
  24. Bone RC: Gram-positive organisms and sepsis. Arch Intern Med 1994;154:26–34.
  25. Madani TA, Al-Abdullah NA, Al-Sanousi AA, Ghabrah TM, Afandi ZZ, Bajunid HA: Methicillin-resistant Staphylococcus aureus in two tertiary-care centers in Jeddah, Saudi Arabia. Infect Control Hosp Epidemiol 2001;22:211–216.
  26. Hurley JC: Concordance of endotoxemia with gram-negative bacteremia in patients with gram-negative sepsis: A meta-analysis. J Clin Microbiol 1994;32:2120–2127.
  27. Yoshida T, Hirawatsu K: Potent in vitro bactericidal activity of polymyxin B against methicillin-resistant Staphylococcus aureus. Microbiol Immunol 1993;37:853–859.
  28. Jaber BL, Barrett TW, Cendoroglo Neto M, Sundaram S, King AJ, Pereira BJG: Removal of cytokine inducing substances by polymyxin-B immobilized polystyrene-derivative fibers during in vitro hemoperfusion of 10% human plasma containing Staphylococcus aureus challenge. ASAIO J 1998;44:48–53.
  29. Iwama H, Komatsu T: Effect of an endotoxin-removing column containing immobilized polymyxin B fiber in a patient with septic shock from gram-positive infection. Acta Anaesthesiol Scand 1998;42:1–4.
  30. Schlievert PM: Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic endotoxin type C. Infect Immunol 1981;26:123–128.
  31. Brenchley P: VEGF/VPF: A modulator of microvascular function with potential roles in glomerular pathophysiology. J Nephrol 1996;9:10–17.
  32. Brown LF, Berse B, Tognazzi K, Manseau EJ, van de Water L, Senger DR, Dvorak HF, Rosen S: Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992;42:1457–1461.
  33. Hovind P, Tarnow L, Oestergaard PB, Parving HM: Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57(suppl 75):S56–S61.
  34. Itaya H, Imaizumi T, Yoshida H, Koyama M, Suzuki S, Satoh K: Expression of vascular endothelial growth factor in human monocyte/macrophages stimulated with lipopolysaccharide. Thromb Haemost 2001;85:171–176.
  35. Nielsen HJ, Werther K, Mynster T, Svendsen MN, Rosendahl S, Elley T, Skov F: Bacteria-induced release of white cell and platelet-derived vascular endothelial growth factor in vitro. Vox Sang 2001;80:170–178.
  36. Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK, Won NH: Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int 2000;58(suppl 77):S104–S112.
  37. Webb JAN, Watson CJ, Roberts ISD, Bottomley MJ, Jones CA, Lewis MA, Postlethwaite RJ, Brenchley EC: Circulating vascular endothelial growth factor is not increased during relapse of steroid-sensitive nephrotic syndrome. Kidney Int 1999;55:1063–1071.
  38. Matsumoto K, Kanmatsuse K: Elevated vascular endothelial growth factor levels in the urine of patients with minimal change nephrotic syndrome. Clin Nephrol 2001;55:269–274.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50